These observations suggested that low injected mass of radiolabelled PARP inhibitors may not alter target expression, and treatment of either olaparib (> 0.04 μg) or EBRT may induce DNA damages, hence resulting in the upregulation of PARP expression and uptake of radiolabelled PARP inhibitor in the tumour. The gene discussed is PARP1; the disease is neoplasm.